Ariad Pharmaceuticals (ARIA) and Cascadian Therapeutics (CASC) Head-To-Head Analysis

Ariad Pharmaceuticals (NASDAQ: ARIA) and Cascadian Therapeutics (NASDAQ:CASC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

87.0% of Ariad Pharmaceuticals shares are held by institutional investors. Comparatively, 81.4% of Cascadian Therapeutics shares are held by institutional investors. 8.2% of Ariad Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of Cascadian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ariad Pharmaceuticals and Cascadian Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ariad Pharmaceuticals -60.47% N/A -17.16%
Cascadian Therapeutics N/A -43.53% -40.90%

Analyst Recommendations

This is a breakdown of recent ratings for Ariad Pharmaceuticals and Cascadian Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ariad Pharmaceuticals 0 0 0 0 N/A
Cascadian Therapeutics 1 2 2 0 2.20

Cascadian Therapeutics has a consensus target price of $7.00, indicating a potential downside of 30.14%. Given Cascadian Therapeutics’ higher possible upside, analysts clearly believe Cascadian Therapeutics is more favorable than Ariad Pharmaceuticals.

Valuation & Earnings

This table compares Ariad Pharmaceuticals and Cascadian Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ariad Pharmaceuticals N/A N/A N/A ($0.18) -133.28
Cascadian Therapeutics N/A N/A -$56.93 million ($1.34) -7.48

Ariad Pharmaceuticals is trading at a lower price-to-earnings ratio than Cascadian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Ariad Pharmaceuticals beats Cascadian Therapeutics on 5 of the 9 factors compared between the two stocks.

Ariad Pharmaceuticals Company Profile

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive News & Ratings for Ariad Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Celanese  Receives New Coverage from Analysts at Barclays
Celanese Receives New Coverage from Analysts at Barclays
Marten Transport  Downgraded to Equal Weight at Stephens
Marten Transport Downgraded to Equal Weight at Stephens
Deutsche Bank Downgrades Church & Dwight  to Hold
Deutsche Bank Downgrades Church & Dwight to Hold
Santander Group  Upgraded by Zacks Investment Research to “Buy”
Santander Group Upgraded by Zacks Investment Research to “Buy”
Macerich  Stock Rating Upgraded by BMO Capital Markets
Macerich Stock Rating Upgraded by BMO Capital Markets
Iberiabank  Downgraded by Zacks Investment Research
Iberiabank Downgraded by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.